|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to many factors including lack of awareness and lack of prostate-specific antigen (PSA) screening, a high percentage of men present with locally advanced and metastatic prostate cancer at diagnosis.
|
31297628 |
2020 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The median PSA at date of diagnosis decreased with 46% from 181 ng/mL in 1998 to 98 ng/mL in 2015.<b>Conclusions:</b> There was an increase in survival among men with <i>de novo</i> metastatic prostate cancer in Sweden between 1998 and 2015.
|
31526166 |
2020 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 121 consecutive patients with recurrent PC as defined by PSMA-ligand PET (median PSA: 1.13ng/ml) underwent PSMA-targeted RGS.
|
30987843 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eligibility included metastatic prostate cancer and at least one: small-cell neuroendocrine morphology; ≥50% neuroendocrine marker expression; new liver metastases without PSA progression; or elevated serum neuroendocrine markers.
|
30232224 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate Cox regression analysis demonstrated that Gleason grade group, prostate-specific antigen nadir (nPSA), and time to PSA nadir (TTN) were risk factors for progression to CRPC in mPCa patients.
|
31632505 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines.
|
29194902 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed 184 patients diagnosed with metastatic prostate cancer and divided them into three PSA level groups as follows: low (<100 ng ml<sup>-1</sup>), intermediate (100-999 ng ml<sup>-1</sup>), and high (≥1000 ng ml<sup>-1</sup>).
|
29735818 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fifty-two patients with metastatic PCa who underwent [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT imaging and serum prostate-specific antigen (PSA) level measurements before and during treatment were investigated.
|
31468235 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HORRAD trial is a multicentre RCT recruiting 432 patients with prostate-specific antigen (PSA) >20ng/ml and primary bone mPCa on bone scan between 2004 and 2014.
|
30266309 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Overall, our results confirmed the HALP score as an independent prognostic factor for PSA-PFS in patients with mPCA or oPCA after cRP.
|
30662528 |
2019 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the metastatic prostate cancer cohort, the expression of four microRNAs (miRNA-125b, -126, -143 and -221), and miRNA-141 in tissue was associated with Gleason score and prostate-specific antigen, respectively.
|
29775158 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of the current study was to evaluate the factors and outcomes associated with increased imaging and serum prostate-specific antigen use in men with mPCa.
|
29579318 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
|
29855278 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
|
29663462 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our clinical observations demonstrate that CTL immunotherapy is a viable treatment option for PC patients, particularly those with bone metastatic lesions and high serum levels of PSA and FPSA.
|
29901632 |
2018 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eligible patients had metastatic prostate cancer and a PSA level higher than 4.0 ng/mL between 6 and 12 months after starting ADT.
|
28358937 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
This could be used to select men for entry at the time of PSA nadir onto randomized trials evaluating the impact on survival of salvage androgen deprivation therapy with or without agents shown to prolong survival in men with castrate-resistant metastatic prostate cancer.
|
28097317 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with PSA value > 4 ng/ml and clinical suspicion of PCa were included.
|
29050295 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A propensity score matching analysis.
|
28588730 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy.
|
26585698 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed outcomes in men with low prostate specific antigen and a high disease burden who received the oral androgen receptor inhibitor enzalutamide in the PREVAIL (Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer) study.
|
28736322 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We retrospectively evaluated the utility of <sup>68</sup>Ga-PSMA-11 PET for planning <sup>223</sup>RaCl<sub>2</sub> therapy of patients with metastatic prostate cancer and its impact on the therapeutic response as determined by prostate-specific antigen (PSA) and alkaline phosphatase (ALP), as well as the correlation of PSA changes with the results of prostate-specific membrane antigen (PSMA) PET follow-up scans.
|
27660148 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A retrospective analysis of a single-institution cohort of men with castration-resistant, metastatic prostate cancer was performed to determine the association between carrier status of pathogenic BRCA2 germline variants and prostate-specific antigen response to carboplatin-based chemotherapy.
|
28608931 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the interim, we propose a practical approach to prostate cancer screening for men with a germline mutation in a known/suspected moderate to high-penetrance cancer predisposition gene (eg, BRCA1/2), and/or men with a first- or second-degree relative with metastatic prostate cancer (regardless of genetic testing): baseline prostate-specific antigen and digital rectal exam by experienced providers at age 40 years or 5 years earlier than age of diagnosis of the youngest first- or second-degree relative with metastatic prostate cancer, whichever is earlier.
|
28697982 |
2017 |
|
Metastasis from malignant tumor of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metastatic prostate cancer in the modern era of PSA screening.
|
28338310 |
2017 |